Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIRB2: Biweekly S-1, Irinotecan, and Bevacizumab in Advanced Colorectal Cancer
NCT03380689Phase 1Withdrawn
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jan 2018
- Primary completion
- Jul 2018
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tegafur, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and bevacizumab in metastatic colorectal cancer (mCRC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Maximum Tolerance Dose at 12 months. Planned start Jan 2018; status: withdrawn.
02
Drugs
tegafuririnotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabbevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03380689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03380689.